Q4 2024 Management View CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 11:53 am Looking ...

AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset. The drugmaker ...

Read about AbbVie, Novartis, ResMed and more in the latest Market Talks covering the Health Care sector.

The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...

AbbVie stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat ...

Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie ...

AbbVie shares surged nearly 8% Friday morning, after the company substantially raised its sales forecasts for two key drugs. While reporting fourth-quarter revenue and earnings per share above Wall ...